STABL — Stayble Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK14.03m
- SEK12.43m
Brief: Stayble Therapeutics To Apply For Bankruptcy
Brief: Stayble Therapeutics Q1 EBIT Loss Narrows To SEK 6.9 Mln
Brief: Stayble Therapeutics Enters Into LoI On Potential Strategic Collaboration, Financing
Brief: Stayble Therapeutics Q4 Oper Loss To SEK 1.5 Mln
Brief: Stayble Therapeutics Updates On Progress In Finding Partner For STA363
Brief: Stayble Therapeutics Q2 EBIT Loss Narrows To SEK 1.9 Mln
Brief: Stayble Therapeutics Q1 EBIT Loss At About SEK 2 Mln
Brief: Stayble Therapeutics Raises SEK 4.55 Mln Through Issue
Brief: Stayble Therapeutics Carries Out Directed Issue Of Units
Brief: Stayble Therapeutics Q4 EBIT Loss SEK 3.2 Mln
Brief: Stayble Therapeutics Receives SEK 2.6 Mln From Excercise Of Warrants
Brief: Stayble Therapeutics Q3 EBIT Loss SEK 2.3 Mln
Brief: Stayble Therapeutics Says Positive Results From Company's Clinical Phase 1B Study In Lumbar Disc Herniation
Brief: European Patent Intends To Grant Stayble Patent For Treatment Of Disc Herniation
Brief: Stayble Therapeutics Gets Approved Patent In South Africa For Treatment Of Disc Herniation
Brief: Stayble Therapeutics Q2 EBIT Loss Narrows To SEK 3.4 Mln
Brief: Stayble Therapeutics Appoints Erik Kullgren As CFO
Brief: Stayble Therapeutics Q4 EBIT Loss Widens To SEK 6.5 Mln
Brief: Stayble Therapeutics Phase IIB Study Does Not Meet Primary Endpoint